Kardigan, Inc.

NASDAQ:KARD

Biotechnology

Healthcare
$12.32 +3.50%

+$0.77 today

Market cap
$1.10B
Beta
0.00
52W Low $16.25High $24.00

Volume 0.55M

Average 5.84M

KARD Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

No reported Accounts Receivables figures are available to summarize.

Accounts Receivables history

Currency unavailable · from the cash flow

No Accounts Receivables data reported for this period type.

Accounts Receivables vs competitors

How KARD compares with its peers on the latest reported figures

KARD Competitors
Accounts Receivables for KARD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYTKCytokinetics, IncorporatedLTM Jun 2026$16.02M USD+90.5%—22.6%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$10.63M USD——4723.1%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$5.16M USD+1145.6%+46.9%72.4%
IKTInhibikase Therapeutics, Inc.LTM Mar 2026$0 USD———
RNAAtrium Therapeutics, Inc.FY2025$0 USD——0.0%
KARDKardigan, Inc.—— ———
Peer median (excluding KARD) —+618.1%+46.9%47.5%

Competitors are the stored peer set for KARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Kardigan, Inc.

NASDAQ:KARD

Intrinsic Alpha fair value

Locked

Current Price

$12.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.